A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma

Cancer

Volumn 94, Issue 7, 2002, Pages 1925-1930

  Seo, Jae H ^a   Whang, Young M ^a   Kim, Byung S ^a   Choi, Chul W ^a   Shin, Sang W ^a   Kim, Yeul H ^a   Kim, Jun S ^a,b   Goo, Bum H ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Anthracycline resistance; Breast carcinoma; Ifosfamide; Paclitaxel

Indexed keywords

'LEUCOGEN'; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL;

ADULT; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL RATE;

EID: 0036534343     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10431     Document Type: Article

References (25)

1. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
2. High-dose chemotherapy of breast cancer: Current status and developmental strategies
3. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agents from Taxus brevifolia
4. The chemistry of paclitaxel, a clinically useful anticancer agent
5. Current options in treatment of anthracycline-resistant breast cancer
6. Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer
7. Ifosfamide. European perspective
8. Paclitaxel as secondary and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
9. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial
10. Activity of taxol by 3 h infusion in breast cancer patients with clinical resistance to anthracyclines
11. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: A phase I/II trial of 96-hour infusion
12. Multicenter, randomized comparative study of paclitaxel in patients with metastatic breast cancer
13. Review of recent trial of chemotherapy for advanced breast cancer: The taxens
14. The taxoids: Paclitaxel and docetaxel
15. Vinorelbine: An overview
16. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
17. Paclitaxel by 3 h infusion and carboplatin in anthracycline resistant advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
18. Cisplatinum-taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer
19. Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second line treatment of metastatic breast cancer: Results of a phase II study
20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in treatment of advanced breast cancer
21. Activity of ifosfamide in breast cancer
22. Ifosfamide, methotrexate and 5-FU in advanced pretreated breast cancer
23. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer
24. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: A phase II study
25. A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors